ARTICLE | Clinical News
LOXO-101: Phase II started
November 16, 2015 8:00 AM UTC
The NCI selected Loxo’s LOXO-101 to join the ongoing, open-label, U.S. Phase II NCI-MATCH trial to treat patients harboring Trk gene fusions. Loxo has exclusive, worldwide rights to LOXO-101 from Arra...